Advertisement
Arroz Hidrolizado
Article not rated

Vol. 25 - Num. 100

Clinical Reviews in Digestive Diseases

Finally responds to something!

Iván Carabaño Aguadoa, M.ª Concepción Garrido Ruizb, Enrique Salcedo Lobatoa, Enrique Medina Beníteza

aSección de Gastroenterología, Hepatología y Nutrición Pediátrica. Servicio de Pediatría. Hospital Universitario 12 de Octubre. Madrid. España.
bServicio de Anatomía Patológica. Hospital Universitario 12 de Octubre. Madrid. España.

Correspondence: I Carabaño. E-mail: carabano1975@hotmail.com

Reference of this article: Carabaño Aguado I, Garrido Ruiz MC, Salcedo Lobato E, Medina Benítez E. Finally responds to something! . Rev Pediatr Aten Primaria. 2023;25:421-4. https://doi.org/10.60147/87c527ca

Published in Internet: 19-12-2023 - Visits: 2108

Abstract

Eosinophilic esophagitis is a chronic immune-mediated disease whose incidence has been increasing in recent years. It preferentially, but not exclusively, affects men and people with a history of atopy. It is estimated that the current prevalence in developed countries exceeds 100 cases per 100,000 inhabitants. It is the most common cause of dysphagia and food impaction throughout the pediatric age, and has a negative impact on quality of life. It affects boys more than girls. Its first therapeutic step consists of: exclusion diets, proton pump inhibitors and swallowed topical corticosteroids. In refractory cases, dupilumab, a biologic with anti-interleukin 4 and 13 capacity, can be used with very promising results.

Keywords

Dupilumab Eosinophilic esophagitis

Comments

This article has no comments yet.